Novocure (NSDQ:NVCR) shares were up 6% after hours yesterday after the company released positive data for its “tumor treating fields” combined with chemotherapy for pancreatic and ovarian cancer. The St. Helier, N.J.-based company’s TTFields are low-intensity, alternating electric fields meant to inhibit cancer cell replication and cause cell death.
Novocure presented data from its phase II pilot Panova study, evaluating TTFields in combination with chemotherapy drugs nab-paclitaxel and gemcitabine in patients with advanced pancreatic cancer. The data suggested that the combination therapy may be tolerable and safe. The company also reported that patients who received TTFields and chemotherapy had an improved 1 year survival rate compared to those who received only chemotherapy.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure touts positive TTFields data for pancreatic, ovarian cancer appeared first on MassDevice.
from MassDevice http://ift.tt/2hituJM
Cap comentari:
Publica un comentari a l'entrada